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The increasing global prevalence of chronic kidney disease
(CKD) and end-stage renal disease with the associated
spiraling cost has profound public health and economic
implications. This has made slowing the progression of CKD,
a major health-care priority. CKD is invariably characterized
by progressive kidney fibrosis and at present, treatment
aiming to slow the progression of CKD is limited to
aggressive blood pressure control, with few therapies
targeting the fibrotic process itself. In this review, we explore
the potential of experimental therapeutic strategies, based
on preventing or reversing the pathophysiologic steps of
kidney remodeling that lead to fibrosis.
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Recent reports suggest that up to 10% of the population may
be affected by chronic kidney disease (CKD).1,2 The global
pandemic of CKD is fueled by population ageing as well as
the rise in the numbers of those affected by diabetes, obesity,
and hypertension. The rising tide of CKD has major health-
care repercussions not only in terms of end-stage renal
disease service provisions but also in view of its major
multiplier impact on cardiovascular disease.
Irrespective of the underlying cause, progressive CKD is
characterized histologically by the concurrent development of
glomerulosclerosis and tubulointerstitial fibrosis. Podocyte
damage and loss has been identified as a key mechanism, at
which a number of glomerular pathomechanisms converge to
result in glomerulosclerosis.3,4 The mesangial cell is the major
matrix forming cell in the glomerulus and is also pivotal to the
glomerulosclerotic process, while the activated (a-smooth
muscle actin-positive) interstitial fibroblast or myofibroblast
is central to the development of tubulointerstitial fibrosis. The
particular importance of tubulointerstitial damage in progres-
sive CKD was highlighted in an extensive systematic morpho-
metric analysis of over 1700 renal biopsies, which showed that
interstitial inflammation and fibrosis were significantly
associated with a more rapid decline of kidney function.5
Furthermore, analysis of interstitial fibroblasts from diseased
kidneys demonstrated that these cells played a key role in
fibrogenesis due to increased proliferative activity and their
ability to synthesize extracellular matrix (ECM) proteins.6 The
cellular mechanisms underlying this fibrotic process are
characterized by kidney cell loss through necrosis and
apoptosis, epithelial–mesenchymal transformation (EMT)
(reversal to an embryonic phenotype), and proliferation of
myofibroblasts with subsequent increased ECM synthesis along
with decreased breakdown and clearance of ECM (Figure 1).
Currently, treatment of CKD is mostly limited to
aggressive control of hypertension with a particular focus
on agents inhibiting the renin–angiotensin–aldosterone sys-
tem, which have been reviewed extensively elsewhere.7
However, so far there are no clinical therapies specifically
targeting kidney remodeling and the ensuing fibrotic process
itself. In this review, we discuss a number of therapeutic
approaches that have the potential of being translated to the
clinical arena within the foreseeable future. In particular, we
will focus on experimental therapies targeting the key cellular
events that are central to kidney fibrosis, namely cellular loss,
transformation, proliferation, and ECM accumulation.
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TARGETING CELLULAR EVENTS UNDERLYING FIBROSIS
Cell loss and proliferation
The response to glomerular and tubulointerstitial cell injury
in kidney diseases invariably involves changes in cell number
(i.e. cell proliferation, apoptosis, and necrosis) and/or cell
size (hypertrophy). These events typically precede the
accumulation of ECM, and therefore the balance between
these differing processes determines whether the response to
an insult to the kidney leads to resolution of glomerular/
tubulointerstitial injury and healing, or results in progressive
fibrosis and scarring (Figure 1). Thus pharmacological
manipulation of these factors may modulate the fibrotic
process in CKD.
Cell loss
Loss of intrinsic glomerular and tubular epithelial cells is
likely to play a pivotal role in the initiation and progression
of CKD. Loss of mesangial cells through apoptosis has been
implicated in the initiation of glomerulosclerosis in a number
of experimental models of glomerulonephritis.8 In the anti-
Thy1.1 glomerulonephritis model, mesangial apoptosis is
followed by mesangial repair through migration into the
glomerulus and proliferation of mesangial remnants.8,9 While
mesangial cell apoptosis is an essential mechanism in
normalizing cell number during the reparative mesangiopro-
liferative response to glomerular injury as in the anti-Thy1.1
nephritis model, excessive apoptosis promotes glomerulo-
sclerosis.10 Loss of glomerular endothelial and epithelial cells
has also been associated with glomerulosclerosis.11 Podocyte
loss through apoptosis, with consequent denudement of the
glomerular basement membrane and the formation of
capsular adhesions, has been shown to initiate glomerulo-
sclerosis.3,4,12 Tubular epithelial cell apoptosis in excess of
proliferation is a key factor in the development of both acute
and chronic tubulointerstitial fibrosis. Indeed in both
immune- and nonimmune-mediated models of CKD, we
and others have noted a progressive increase in kidney cell
apoptosis as tubular atrophy and kidney scarring progress.8,13
These histological manifestations of scarring were associated
with the activation of a number of pro-apoptotic pathways,
the upregulation of pro-apoptotic genes and proteins,
including those involved in the caspase enzymatic system,
and a parallel downregulation of apoptosis inhibitors such as
Bcl2.14 Thus targeting these pro-apoptotic mediators may
attenuate the fibrotic response to tissue injury. For example,
administration of a pan-caspase inhibitor, B-D-FMK, in the
nephrotoxic serum nephritis model, significantly decreased
glomerular inflammation and reduced both glomerular and
interstitial fibrosis. This was associated with the preservation
of kidney cell number and a significant reduction in
proteinuria.13
While such therapies appear promising it is important to
recognize that under certain circumstances apoptosis may
actually promote tissue healing in glomerulonephritis by
clearing excessive numbers of resident glomerular cells and
infiltrating inflammatory cells.15 Thus, therapies targeting
apoptosis may have a double-edged effect—on the one hand,
decreasing the generation of the pro-inflammatory cytokines
such as interleukin-1,13 known to be activated by the caspase
enzymatic system, while on the other simultaneously
preventing the clearance of pro-inflammatory cells within
damaged kidneys thereby hampering recovery.
Cell proliferation
It is widely accepted that a-smooth muscle actin-positive
myofibroblasts are the principal effector cells in fibrogenesis,
with increased proliferation of myofibroblasts preceding
ECM expansion in both glomerular and tubulointerstitial
compartments.16 Therefore therapies targeting mediators of
myofibroblast formation and proliferation such as extra-
cellular mitogens, cell-cycle proteins, and intracellular
signaling pathways may have therapeutic benefit in kidney
fibrosis.
Platelet-derived growth factor (PDGF) is a potent renal
glomerular cell and fibroblast mitogen. Its inhibition is
effective in reducing experimental glomerular inflammatory
and proliferative changes. A number of agents have been
shown to target PDGF in models of proliferative glomeru-
lonephritis including PDGF aptamers and Trapidil, an anti-
platelet agent that is a potent PDGF antagonist.17 Imatinib
mesylate is a c-abl tyrosine kinase inhibitor, which also blocks
the PDGF receptor and is used for the treatment of chronic
myeloid leukemia. It was found to be effective in reducing
kidney injury in experimental mesangioproliferative glomeru-
lonephritis and attenuated kidney fibrosis in animal models
of chronic allograft nephropathy, obstructive as well as
diabetic nephropathy.17 However, imatinib exhibits some
cardiotoxicity and affects bone remodeling,18,19 and trials in
renal patients have been placed on hold by the manufacturer;
later generation tyrosine kinase inhibitors are currently being
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Figure 1 | The cellular mechanisms underlying this fibrotic
process are characterized by kidney cell loss through necrosis
and apoptosis, EMT (reversal to an embryonic phenotype),
and proliferation of myofibroblasts with subsequent increased
ECM synthesis along with decreased breakdown and clearance
of ECM.
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tested for potentially better safety profiles. Other more
specific strategies targeting PDGF are already available. For
instance, antagonism of PDGF-D with the human mono-
clonal antibody CR002 is effective in preventing scarring in
the anti-Thy1.1 glomerulonephritis model and this antibody
has already completed a phase I clinical study.17
Epidermal growth factor (EGF) stimulates kidney fibro-
blast proliferation and collagen expression in vitro. Inhibiting
EGF preserves kidney function in a model of polycystic
kidney disease and attenuates glomerular fibrosis in a model
of fibrosis and hypertension.20 A number of agents targeting
EGF signaling are in therapeutic use in a variety of human
cancers. In vivo work using these inhibitors may help clarify
the role of EGF in kidney fibrosis. Of relevance is the role
played by the EGF receptor (EGFR) in the progression of
kidney scarring; transgenic mice harboring a dominant-
negative form of EGFR is resistant to the progression of renal
lesions induced by nephron reduction or angiotensin
infusion.21 Also, tissue growth factor-a (TGFa), an EGFR
ligand, and its sheddase tumor necrosis factor-a converting
enzyme are overexpressed after angiotensin infusion, and
angiotensin-induced renal lesions are blunted in TGFa
knockout mice and by pharmacological tumor necrosis
factor-a converting enzyme blockade. Experimental data
suggest that EGFR transactivation by angiotensin also plays a
key role in renal functional deterioration and that pharma-
cological inhibitors of tumor necrosis factor-a converting
enzyme might be useful for preventing the progression
of CKD.21
Basic fibroblast growth factor-2 (FGF-2) is expressed in
normal kidneys and is mitogenic for a variety of cells
including mesangial,22 proximal-tubular epithelial,23 glomeru-
lar endothelial,24 and glomerular epithelial cells.25 Further-
more, FGF-2 expression correlates strongly with scarring in
human kidneys with tubulointerstitial fibrosis and is an
inducer of both fibroblast proliferation26 and EMT.27 In
addition, FGF-2 appears to promote podocyte injury,28 and
targeting FGF-2 attenuates renal injury in anti-Thy1.1
nephritis.29 There is increasing interest in targeting FGF-2
due to the key role it plays in angiogenesis in a variety of
human cancers and inflammatory conditions such as
rheumatoid arthritis.30 The use of such agents in in vivo
models of kidney disease will help determine their ther-
apeutic potential in CKD.
Proliferation and cell-cycle progression is ultimately
regulated by specific proteins known as cyclins, cyclin-
dependent kinases, and cyclin-dependent kinases inhibitors.
As well as controlling cell proliferation, cell-cycle regulatory
proteins also regulate other biologic processes central to the
fibrotic process including cellular hypertrophy, differentia-
tion, and apoptosis. The synthetic cyclin-dependent kinases
inhibitor roscovitine has beneficial effects on kidney function
and histology in anti-Thy1.1 nephritis, and a human
immunodeficiency virus-1 transgenic mouse model of
collapsing glomerulopathy.31,32 Furthermore, the inhibitory
effect of roscovitine on cell-cycle progression has also been
shown to be effective at inhibiting cystogenesis in a murine
model of polycystic kidney disease.33 Roscovitine is already in
clinical trials for cancer, and cyclin-dependent kinases
inhibitors may have a valuable therapeutic role in inhibiting
myofibroblast proliferation and fibrosis.
The Ras–Raf–Mek–Erk and the Rho kinase (ROCK)
signaling pathways not only play a key role in regulating
cellular proliferation but also can amplify TGFb-mediated
fibrotic responses34 (see below). Targeting the Ras–Raf–Me-
k–Erk pathway using the Ras antagonist farnesylthiosalicylic
acid or with the Mek inhibitor UO126 has reduced kidney
injury in models such as anti-Thy1.1 nephritis,35,36 cisplatin-
induced renal failure,37 and a murine model of polycystic
disease.38 A number of inhibitors targeting this pathway are
already in use in oncology,36 these drugs may be promising
therapeutics in progressive CKD. Statins also attenuate
fibrogenesis in a number of in vivo models such as nephrotoxic
nephritis,39 and there is a body of evidence to suggest that
these effects are mediated by the inhibition of Ras signaling (by
depleting prenylation substrates) rather than by cholesterol
reduction.40 Clinical trials are underway to assess full potential
of statins in the management of progressive CKD.
Fasudil, a ROCK inhibitor, is used in the treatment of
cerebral vasospasm in Japan and clinical trials are underway
to assess its efficacy in cardiovascular disease. ROCK
inhibitors attenuate interstitial fibrosis in unilateral ureteric
obstruction (UUO), subtotal nephrectomy, and hypertensive
models of glomerulosclerosis.41 Interestingly, ROCK1 knock-
out mice are not protected from kidney fibrosis following
UUO,42 suggesting that ROCK inhibitors may mediate their
effects through targeting other kinases such as ROCK2.
Experimental data support the evaluation of ROCK inhibi-
tors in CKD.
Again with a plethora of anti-proliferative therapies
emerging, it is important to recognize that cell proliferation
may be an essential reparative response to injury (as in anti-
Thy1.1 nephritis), and therefore inhibiting cellular prolifera-
tion in some circumstances could aggravate injury.
Cell transformation
While the cellular response to injury may involve cell loss
and/or proliferation, some cells regress to an embryonic
mesenchymal phenotype, allowing their regeneration
through proliferation thereby restoring the kidney structural
integrity. Other cells are transformed to a mesenchymal/
myofibroblastic phenotype thus contributing to pool of
fibroblasts that migrate, proliferate, secrete excess interstitial
collagens, and hence promote ECM expansion and fibrosis. A
large body of literature deals with such EMT of kidney cells
and its role in kidney fibrogenesis.43 A number of mediators
have been implicated in the stimulation of EMT, most
notably TGF-b1 but also interleukin-1, connective tissue
growth factor, EGF, PDGF as well as advanced glycation end
products. There is strong data suggesting that TGF-b1
mediates its effects via the focal adhesion adapter protein,
Hic-5, which is RhoA/ROCK1-dependent.44
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Consequently, interventions targeting EMT or the stimu-
lation of mesenchymal–epithelial transformation may have
therapeutic appeal. For example, inhibiting TGF-b1 activity
with neutralizing antibodies,45 receptor antagonists46 as well
as the inhibition of TGF-b1 gene transcription47 has
attenuated fibrosis in a number of experimental models such
as anti-Thy1.1 nephritis and diabetic nephropathy.48
More recent strategies have focused on targeting TGF-
b1-mediated signal transduction either through the blockade
of its receptor activin-like kinase or the manipulation of its
intracellular transduction mediators, the Smads. For exam-
ple, IN-1130 a small molecule inhibitor of activin-like kinase-
5 attenuated fibrotic changes in UUO.49 Hepatocyte growth
factor inhibits TGF-b1–Smad signal transduction by inhibit-
ing nuclear translocation of Smads or by upregulating the
expression of Smad corepressors.50 Hepatocyte growth factor
has been effective in reducing fibrosis in experimental models
of CKD where EMT is thought to play a significant role in
fibrogenesis such as obstructive uropathy,51 diabetic ne-
phrectomy,52 and chronic allograft nephropathy.53
Bone morphogenetic protein-7 (BMP-7) is another
endogenous mediator that inhibits TGF-b1–Smad signaling
via upregulation of inhibitory Smads.54 BMP-7 inhibits not
only EMT but may reverse established fibrosis through
mesenchymal–epithelial transformation in models such as
serum nephrotoxic nephritis54 and UUO.55 Furthermore,
BMP-7 may attenuate vascular56 and skeletal complications
of CKD.57 In addition, targeting endogenous antagonists of
BMP activity58 such as uterine sensitization-associated gene-1
and sclerostin may also have therapeutic potential.59 Uterine
sensitization-associated gene-1 is abundantly expressed in the
kidney. Uterine sensitization-associated gene-1 knockout
mice show preserved kidney function after acute and chronic
kidney damage.59 In contrast, the cysteine-rich protein
Kielin/chordin-like protein (KCP) stimulates BMP-7 signal-
ing, and KCP-deficient mice have been found to be
susceptible to developing renal interstitial fibrosis.60 While
BMP-7 and hepatocyte growth factor are in early clinical
development, at present, their potential to stimulate
mesenchymal–epithelial transformation represents an excit-
ing development in the treatment of fibrotic kidney disease.
Other TGF-b1 antagonists include small leucine-rich
proteoglycans such as decorin and biglycan, which can
antagonize TGF-b1-mediated experimental fibrosis possibly
by sequestering TGF-b1 in the ECM, thereby reducing its
biological activity. Furthermore, local targeting of TGF-b1
signaling by upregulating the expression of inhibitory Smads
such as Smad7 has attenuated interstitial fibrosis in animals
submitted to UUO.61 Such gene delivery is an interesting
experimental tool but its clinical utility remains somewhat
limited.
Inflammation
Experimental and clinical kidney fibrosis is often preceded by
an interstitial inflammatory response as reviewed by
Chatziantoniou and Dussaule.62 It is mediated by the
infiltration of the interstitium by lymphocytes, monocytes,
and macrophages through the activation of a number of
cytokines and chemokines. These inflammatory cells mediate
tubulointerstitial injury by a number of mechanisms that
include the production of reactive oxygen species, secretion of
vasoactive hormones, and profibrotic growth factors such as
TGF-b1. While it is beyond the scope of this review to discuss
the impact of inflammatory cell modulation, and the
inhibition of cytokines as well as chemokines on the
development of kidney fibrosis, recent advances warrant
highlighting. Many chemokines and their receptors, CXCL13,
CX3CR1, CCR1, CCR2, MCP-1, and osteopontin, are
upregulated in damaged kidneys, thus contributing to the
initiation of the inflammatory response and fibrosis. Some of
these chemokines, including MCP-1, have been shown to be
released by damaged or transformed tubules cells. Blocking of
CCR2, a receptor of MCP-1, decreased infiltration and
activation of macrophages with subsequent amelioration of
progressive fibrosis following UUO.63 Neutralizing MCP-1
with either a specific antibody or gene therapy delayed
clearance of apoptotic neutrophils in a rat model of
tubulointerstitial nephritis and ameliorated progressive fibro-
sis.64 It also reduced renal fibrosis associated with protein-
overload proteinuria65 and interstitial fibrosis in crescentic
glomerulonephritis.66 Blockade of CCR1 (a receptor for a
number of chemokine ligands including RANTES/CCL5, MIP-
1a/CCL3, and MIP-1b/CCL4) by CX471 injection substantially
reduced interstitial leukocyte accumulation and the subse-
quent kidney fibrosis in a murine model of nephrotic
syndrome and focal segmental glomerulosclerosis.67 This
approach has also proved effective in preventing the progres-
sion of lupus nephritis in MRL-Fas(lpr) mice,68 and in
reducing kidney fibrosis after UUO.69 Blocking CX3CR1 (a
receptor for the chemokine CX3CL1 or fractalkine), by both
gene inactivation and target protein blockade, was capable of
reducing inflammation and fibrosis following ischemic kidney
injury.70 Chemokine antagonists and receptor blockers are
being developed to treat a number of inflammatory conditions
and their application to the treatment of clinical kidney
inflammation and fibrosis is promising.
A number of cell-signaling pathways are central in
mediating the inflammatory and fibrotic responses to kidney
injury. For example, the protein kinase C signaling pathway
plays a key role in diabetic nephropathy by upregulating
osteopontin expression, thereby promoting macrophage
recruitment and TGF-b1 production.71 Protein kinase C
inhibitors have attenuated interstitial fibrosis in experimental
models of diabetic nephropathy.72 The protein kinase C
inhibitor, ruboxistaurin, is currently in clinical trials and early
data suggest that it may reduce albuminuria and stabilize
kidney function in patients with diabetic nephropathy.73
A number of pro-inflammatory cytokines and pro-fibrotic
factors, such as PDGF and TGF-b1, also activate the p38
mitogen-activated protein kinase (MAPK). Blockade of p38
MAPK inhibits TGF-b1-induced collagen expression in
fibroblasts and mesangial cells in vitro.74,75 A p38 MAPK
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Table 1 | Potential therapeutic agents and targets in CKD
Target Intervention Mechanism of action Evidence level
TGF-b1 Bone morphogenetic protein-7 Inhibitor of the TGF-b1–Smad
signalling pathway
Experimental models of kidney disease
Hepatocyte growth factor Inhibits nuclear translocation of
receptor-regulated Smads and
upregulates the expression of Smad
corepressors
Experimental models of kidney disease
and trials in promoting angiogenesis
Inhibition of connective tissue
growth factor
Mediator of TGF-b1-induced fibrosis Experimental of kidney disease and
phase II trial completed in diabetic
nephropathy
Tranilast Inhibits TGF-b1-induced ECM
synthesis
Experimental models of kidney disease,
early clinical data in diabetic
nephropathy, and used in the treatment
of hypertrophic scars and scleroderma
Decorin Sequesters TGF-b1 in the
extracellular matrix
Experimental models of kidney disease
Proliferative
mitogens
Anti-platelet-derived growth factor,
for example PDGF aptamers,
imatinib mesylate, CR002, trapidil
Imatinib mesylate—kinase inhibitor
of PDGF transduction. CR002
monoclonal antibody targeting
PDGF-D
Experimental data indicates potential of
CR002 in mesnagioproliferative
disease—phase I trial completed.
Cardiotoxicity limits the use of imatinib
mesylate in clinical use in oncology and
beneficial effects in experimental models
of kidney disease.
Anti-epidermal growth factor Inhibition of renal fibroblast
proliferation and collagen
expression
Experimental models of kidney disease
Intracellular
transduction
cascade
Ras–Raf–Mek–Erk pathway inhibition
by Ras: prenylation inhibitors
(statins), prenyltransferase
inhibitors, farnesylthiosalicylic acid,
Raf and Mek kinase inhibitors
Inhibition of cellular proliferation,
differentiation, and apoptosis
Experimental models of kidney disease
and phase II clinical trial in cancer
treatment. Role of statins in progressive
CKD not yet defined
Rho kinase inhibition: fasudil Interference with cell proliferation,
tubulointerstitial fibrosis, and
glomerular hemodynamics
Experimental models of kidney disease
and phase II studies in ischemic heart
disease fasudil in clinical use in Japan for
cerebral vasospasm
p38 mitogen-activated protein
kinase inhibitors
Inhibition of pro-inflammatory and
profibrotic mediators
Experimental models of kidney disease
and clinical trials in rheumatoid arthritis
and type I diabetes mellitus
Protein kinase C inhibitors such as
ruboxistaurin
Inhibition of cell growth most
evident in diabetic nephropathy
Experimental models of kidney disease.
Early clinical data with ruboxistaurin in
patients with early diabetic nephropathy
Cell-cycle
Inhibitors
Cyclin-dependent kinases inhibitors
such as roscovitine
Inhibition of cell-cycle progression Experimental models and phase II trials
in cancer
Immuno-
suppressive
agents
Mycophenolate mofetil Inhibitor of inosine
monophosphate dehydrogenase
inhibiting cell proliferation
No clear data on efficacy in progressive
CKD
Rapamycin Interference with cell proliferation
by regulating ribosomal biogenesis
and protein translation
Variable data in experimental models of
kidney disease but can induce
proteinuria. No clinical data on efficacy in
progressive CKD
Other Agents Pentoxyfylline Phosphodiesterase inhibitor
interfering with cell proliferation
and EMT
Experimental models of kidney disease.
Ongoing clinical trials assessing role in
proteinuric CKD
Endothelin antagonists Reduce cellular proliferation and
intra-glomerular hypertension
Experimental models of kidney disease.
Ongoing clinical trials in diabetic
nephropathy
Pirfenidone Inhibits ECM accumulation Experimental models of CKD. Phase II
trials in diabetic nephropathy and phase
III in pulmonary fibrosis
Peroxisome proliferator-activated
receptor-g agonists
Reduce cell growth, inflammation.
Antiproteinuric effect
Experimental models of kidney disease
and clinical data. Reduces proteinuria in
diabetic nephropathy. Ongoing clinical
trials in diabetic and non-diabetic CKD
Table 1 continued on following page.
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inhibitor reduced ECM accumulation and renal fibrosis in
UUO76 and the co-administration of a p38 MAPK inhibitor
(SB203580) along with a TGF-b1 receptor inhibitor (activin-
like kinase-5 inhibitor) resulted in a downregulation of TGF-
b1 with reduced myofibroblast accumulation and ECM
deposition.77 A number of p38 MAPK inhibitors are in
clinical trials for the treatment of inflammatory diseases and
these data suggest that such compounds may have useful
anti-fibrotic and anti-inflammatory actions in CKD.
Besides chemokine antagonists and receptor blockers,
advances in the inhibition of the complement system,
another phlogistic pathway, may hold promise. A number
of experimental models have highlighted the role of the
complement system in kidney fibrogenesis. Complement-
deficient mice have proved resistant to the development and
progression of fibrosis following a number of insults.78 Lack
of the naturally occurring complement regulatory protein
Crry led to unrestricted complement activation, marked
inflammation, and progressive kidney failure in mice.79
Inhibition of Crry also exacerbated kidney injury in the
puromycin-induced model of nephrotic syndrome.80 On the
other hand, the systemic administration of the complement
membrane attack complex inhibitor CD59 has been shown to
have therapeutic potential in experimental proteinuric
states.80 Progressive membranous nephropathy has been
associated with raised urinary membrane attack complex
excretion. It would be tempting to speculate that agents
capable of membrane attack complex inhibition, such as
CD59, may have a therapeutic role in such a nephropathy.
Finally, recent data indicate a role of C5 and specifically the
C5a receptor, which is amenable to therapeutic intervention,
in the progression of kidney tubulointerstitial fibrosis.81
There is also increasing interest in vascular endothelial
growth factor-A (VEGF-A or VEGF) that acts as a key
regulator of angiogenesis and vascular permeability. Evidence
is now emerging that begins to elucidate the pathophysio-
logical role of VEFG. For example, both experimental and
clinical data suggest that VEGF is upregulated in diabetic
nephropathy.82 In contrast, the podocyte-specific deletion of
VEGF in mice is associated with failure of glomerular
development and death.83 Interestingly, overexpression of
VEGF resulted in podocyte proliferation and a collapsing
glomerulopathy as seen in HIV infection, while intermediate
levels of VEGF expression were characterized by proteinuria
and endotheliosis analogous to lesions seen in pre-eclamp-
sia.83 Data from in vivo models are conflicting. For example,
exogenous VEGF improved endothelial repair in models of
glomerulonephritis84 and had ameliorated fibrosis and
stabilized kidney function in a remnant kidney model of
progressive CKD. In contrast, blockade of VEGF had
beneficial effects in experimental diabetes85 though interest-
ingly administration of a VEGF antibody in patients with
renal cell cancer, induced proteinuria in 64% patients.86
Given complexity of the VEGF system and the potential
adverse pro-angiogenic effects of VEGF therapy, it is not clear
whether VEGF administration or blockade will have a
therapeutic role in CKD.
Targeting ECM deposition
Targeting ECM deposition would rely on the inhibition of
ECM synthesis or stimulation of its breakdown and
clearance. Not only does TGF-b1 play a pivotal role in
EMT, but it is also a key driver of ECM accumulation by (i)
qualitatively and quantitatively altering the synthesis of key
ECM molecules, (ii) decreasing matrix degradation by
inhibiting proteases as well as activating protease inhibitors
(e.g. plasminogen activator inhibitor-1), and (iii) promoting
cell–matrix interactions by upregulating integrin expres-
sion.87 Therefore, the strategies targeting TGF-b1 highlighted
above may also have beneficial effects on ECM accumulation.
Increased clearance of ECM may depend on the activation
of collagenolytic pathways including metalloproteinases,
which have been shown to be suppressed during the course
of renal fibrosis.88 Alternatively, blockade of tissue inhibitors
of metalloproteinases may be of therapeutic benefit. Little
experimental data are available on interventions directly
targeting these enzymes or the plasminogen activator
collagenolytic pathway though enhancing metalloproteinase
and plasminogen activator activity is a mechanism by which
hepatocyte growth factor enhances ECM clearance.
Work from our own group has highlighted the role of
tissue transglutaminase in the pathogenesis of renal fibrosis.
Tissue transglutaminase irreversibly crosslinks proteins and
collagens rendering ECM resistant to the proteolytic activities
of metalloproteinases. We have observed an upregulation of
tissue transglutaminase expression in a number of experi-
Table 1 | Continued
Target Intervention Mechanism of action Evidence level
Prolyl hydroxylase domain
inhibitors, for example cobalt
chloride, FG-2216
Upregulation of HIF-regulated
genes such as VEGF and EPO
Experimental models of kidney disease.
Phase II clinical trials of FG-2216
underway for the treatment of anaemia
N-acetyl-cysteine Antioxidant Experimental models of kidney disease.
No clinical evidence in CKD
Tocopherols Antioxidant Experimental models of kidney disease.
Tocopherols and a- lipoic acid in clinical
trials in CKD
CKD, chronic kidney disease; ECM, extracellular matrix; EMT, epithelial–mesenchymal transformation; PDGF, platelet-derived growth factor; TGF-a, tissue growth factor-a;
VEGF, vascular endothelial growth factor.
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mental models of fibrosis,89,90 while in human nephropathies
tissue transglutaminase expression correlates with the severity
of interstitial fibrosis.91 Our own research has shown the
potential of specific tissue transglutaminase inhibitors to
attenuate kidney fibrosis in a number of experimental models
of CKD.92 Ongoing work is exploring the clinical potential of
these compounds.
CONCLUSION
In addition to the strategies highlighted above a number of
other therapies summarized in Table 1 may have a role in
progressive CKD. However, nephrologists have so far failed to
address the pathological steps involved in renal remodeling
when attempting to slow the progression of CKD; instead
they have focused their efforts to treating hypertension, a
complication of CKD. This has met with some success;
however, many patients with CKD (EGFRo60 ml/min)
continue to progress to end-stage renal disease. Treatment
strategies based on the manipulation of the underlying
kidney remodeling and scarring process may prove effective
and complementary to current management interventions.
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